AGN argenica therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8

  1. 1,592 Posts.
    lightbulb Created with Sketch. 817
    "see first and last bullet really, first bullet says they have to give a determination in 30 days. They did this, it was on hold. The last bullet says they need to promptly provide a written explanation for why. This is vague and subjective, so they don't need to do this in 30 days."

    To me this is inaccurate. No official determination or explanation has been given inside 30 days, certainly no details were given about the inadequacies of the nonclinical package of the IND submission which is what we're waiting on. Argenica explicitly states this in their 4C.

    The initial reason given in June (inadequate nonclinical package) was informal and not detailed so it doesnt meet the requirements under 21 CFR 312.42 (d).
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
69.0¢
Change
0.000(0.00%)
Mkt cap ! $88.63M
Open High Low Value Volume
70.0¢ 70.0¢ 69.0¢ $48.93K 70.80K

Buyers (Bids)

No. Vol. Price($)
2 14838 68.5¢
 

Sellers (Offers)

Price($) Vol. No.
69.0¢ 29902 1
View Market Depth
Last trade - 14.07pm 07/08/2025 (20 minute delay) ?
AGN (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.